Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease

By Adria Calatayud

Sanofi and Regeneron Pharmaceuticals got approval from European Union regulators for their Dupixent drug as a therapy for chronic obstructive pulmonary disease, adding a new indication for their blockbuster drug.

The companies said Wednesday the latest approval from the European Medicines Agency means the anti-inflammatory drug has now been authorized for six indications in the EU and seven globally. Further regulatory submissions are currently under review, including in the U.S., China and Japan, they said.

The EU medicines regulator is the first authority in the world to approve Dupixent for COPD patients, a disease often linked to smoking and exposure to noxious particles for which there have been no new treatment approaches in more than a decade, the companies said.

Sanofi and Regeneron are jointly developing Dupixent under a global collaboration agreement.

Write to Adria Calatayud at [e-mail]

(END) Dow Jones Newswires

07-03-24 0138ET